gene editing Archives - Page 8 of 15

RCI Names Dr. Mitchell Abrahamsen as EVP & CCO

Recombinetics (RCI) announced that Dr. Mitchell Abrahamsen has joined RCI as Executive Vice President and Chief Commercial Officer. Dr. Abrahamsen will lead product and business development efforts for RCI and its subsidiaries that are commercializing gene-edited animal models for biomedical and agricultural use, Acceligen and Surrogen. Abrahamsen will also continue to [...]

RCI Names Dr. Mitchell Abrahamsen as EVP & CCOIT ADMIN2017-07-07T14:07:48-05:00

Is the Ultimate Beef Herd On Our Doorstep?

Is the Ultimate Beef Herd On Our Doorstep?Adam Davies2020-08-14T16:48:36-05:00

Gene Editing Market to Observe High Growth by 2017 – 2025

Gene Editing Market to Observe High Growth by 2017 – 2025Adam Davies2020-08-14T16:48:58-05:00

Modernization of Healthcare Services to Propel Gene Editing Market

Modernization of Healthcare Services to Propel Gene Editing MarketAdam Davies2020-08-14T16:49:24-05:00

Harmonize Conflicting Regulations For Genetically Engineered Plants and Animals

Harmonize Conflicting Regulations For Genetically Engineered Plants and AnimalsAdam Davies2020-08-14T16:49:43-05:00

Novel Swine Model Developed for Neurofibromatosis Type 1

Novel Swine Model Developed for Neurofibromatosis Type 1Adam Davies2020-08-14T16:50:13-05:00

Recombinetics Announces Major Advancements in the Development of a Novel Swine Model of Neurofibromatosis Type 1

Recombinetics announced the development of the first-of-their-kind gene-edited swine models for Neurofibromatosis Type 1 (NF1). Partially funded by the Children’s Tumor Foundation, and in collaboration with the University of Minnesota, these models are for use in preclinical safety and efficacy testing of therapeutics for this debilitating genetic disease affecting 1 [...]

Recombinetics Announces Major Advancements in the Development of a Novel Swine Model of Neurofibromatosis Type 1Adam Davies2017-05-31T16:06:40-05:00